The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Ahmed, Sagir G ^a  

^a AMINU KANO TEACHING HOSPITAL   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875976997     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.028     Document Type: Article

References (75)

1. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. Bailliere's Clin Haematol. 1993; 6: 215-222. doi:10.1016/S0950-3536(05)80071-X
2. Kaul DK, Fabry ME, Nagel RI. The pathophysiology of vascular obstruction in the sickle cell syndromes. Blood Rev. 1996; 10: 29-44. doi:10.1016/S0268-960X(96)90018-1
3. Fleming AF, Storey J, Molineaux L, et al. Abnormal haemoglobins in the Sudan Savannah area of Nigeria: Prevalence of haemoglobin variants and relationship between sickle cell trait, malaria and survival. Ann Trop Med Parasitol. 1979; 73: 161-172. PMid:315211
4. Hood AT. Protection against lethal malaria in transgenic mice expressing sickle cell haemoglobin. Blood. 1996; 87:1600-1603. PMid:8608253
5. World Health Organization. Sickle Cell Anaemia. 59th World Health Assembly Report. A59/9, Geneva, 2006.
6. Akinkugbe OO. Sickle Cell Disease. In: Akinkugbe OO, ed. Non-communicable diseases in Nigeria. 1st Ed., Lagos, Federal Ministry of Health. 1992; 36-48.
7. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005; 19:785-802. doi:10.1016/j.hoc.2005.07.008 PMid:16214644
8. Mousa SA, Al Momen A, Al Sayegh F, et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost. 2010; 16: 365-376. doi:10.1177/1076029609352661 PMid:20530056
9. William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: basic concepts and causes. Hematology. 2007; 12: 1-13. doi:10.1080/10245330600938422 PMid:17364987
10. Falcao RP, Donadi EA. Infection and immunity in sickle cell disease. AMB Rev Assoc Med Bras. 1989; 35: 70-74. PMid:2695986
11. Overturf GD. Infection and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999; 14: 191-218 PMid:10079855
12. Salawu L, Orimolade EA, Durosinmi MA. Immunohaematological characteristics of Nigerian sickle cell disease patients in asymptomatic steady state. Eur J Gen Med. 2009; 6: 170-174.
13. Dieye TN, Ndiaye O, Ndiaye BO. Complement and serum immunoglobulins in homozygous and heterozygous sickle cell anaemia in Senegal. Dakar Med. 1999; 44: 175-179. PMid:11957280
14. Blacksin MF, Finzel KC, Benevenia J. Osteomyelitis originating in and around bone infarcts giant sequestrum phenomena. Am J Roentgenol. 2001; 176: 387-391. PMid:11159079
15. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997; 337:762-769. doi:10.1056/NEJM199709113371107 PMid:9287233
16. Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev. 2007; 21: 118-133. doi:10.1016/j.tmrv.2006.11.003 PMid:17397762
17. Paitel JF, Guerci AP, Dorvaux V, Lederlin P. Yersinia enterocolitica septicemia, iron overload and deferoxamine. Rev Med Interne. 1995; 16: 705-707. doi:10.1016/0248-8663(96)80775-2
18. Bolarinwa RA, Akinola NO, Aboderin OA, Durosinmi MA. The role of malaria in vaso-occlusive crisis of adult patients with sickle cell disease. J Med Med Sci. 2010; 1: 407-411.
19. Goodman SR. The role of the membrane skeleton in formation of the irreversibly sickled cell: A review. Cell Mol Biol Lett. 1996; 1:105-117.
20. Brittain JE, Han J, Ataga KI, et al. Mechanism of CD47-induced a4ß1integrin activation and adhesion in sickle reticulocytes. J Biol Chem. 2004; 279: 42393-42402. doi:10.1074/jbc. M407631200 PMid:15292185
21. Elion JE, Brun M, Odievre MH, et al. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematol J. 2004; 5: S195-S198. doi:10.1038/sj.thj.6200452 PMid:15190308
22. Akinola NO, Stevens SME, Franklin IM, et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol. 1992; 45: 902-906. doi:10.1136/jcp.45.10.902 PMid:1385483 PMCid:495063
23. Gladwin MT, Vichinsky E. Pulmonary Complications of Sickle Cell Disease. N Engl J Med. 2008; 359: 2254-2265. doi:10.1056/NEJMra0804411 PMid:19020327
24. Holtzclaw JD, Jack D, Aguayo SM, Eckman JR, Roman J, Hsu LL. Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. Am J Respir Crit Care Med. 2004; 169: 687-695. doi:10.1164/rccm.200302-224OC PMid:14684557
25. Sabaa N, de Franceschi L, Bonnin P. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008; 118: 1924-1933. doi:10.1172/JCI33308 PMid:18382768 PMCid:2276396
26. Fawibe AE. Managing acute chest syndrome of sickle cell disease in an African setting. Transac Roy Soc Trop Med Hyg. 2008; 102: 526-531 doi:10.1016/j.trstmh.2008.03.018 PMid:18455745
27. Global Tuberculosis Control: Epidemiology, strategy, financing. WHO report 2009 (Publication no. WHO/HTM/TB/2009.411.). Geneva: World Health Organization; 2009.
28. Ahmed SG, Bukar AA, Jolayemi B. Hematological indices of sickle cell anaemia patients with pulmonary tuberculosis in northern Nigeria. Medit J Hemat Infect Dis. 2010, 2: e2010014,doi10.4084/mjhid.2010.014.doi:10.4084/mjhid.2010.0 14 PMid:21415951 PMCid:3033109
29. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000; 106: 411-420. doi:10.1172/JCI9225 PMid:10930444 PMCid:314325
30. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000; 106:337-338. doi:10.1172/JCI10726 PMid:10930436 PMCid:314335
31. Raphael RI, Vichinsky EP. Pathophysiology and treatment of sickle cell disease. Clin Adv Hematol Oncol. 2005; 3: 492-505. PMid:16167028
32. Fasola F, Adedapo K, Anetor J, Kuti M. Total antioxidants status and some hematological values in sickle cell disease patients in steady state. J Natl Med Assoc. 2007; 99: 891-894. PMid:17722666 PMCid:2574295
33. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with non-phagocyte oxidases. J Leukoc Biol. 2004; 76:760-781. doi:10.1189/jlb.0404216 PMid:15240752
34. Gibson XA, Shartava A, McIntyre J, et al. The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro. Blood. 1998; 91: 4373-4378. PMid:9596687
35. Burkitt MJ, Mason RP. Direct evidence for in vivo hydroxylradical generation in experimental iron overload: an ESR spintrapping investigation. Proc Natl Acad Sci. 1991; 88: 8440-8444. doi:10.1073/pnas.88.19.8440
36. Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion. 2010; 50:1144-1155. doi:10.1111/j.1537-2995.2009.02551.x PMid:20088842
37. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38: 26-34. doi:10.1097/CCM.0b013e3181c98d21 PMid:20083910
38. Francis RB Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis. 1991; 2: 341-353. doi:10.1097/00001721-199104000-00018
39. Shia YT, Udden MM, McIntire LV. Perfusion with sickle cell erythrocytes up regulates ICAM-1 and VCAM-1 genes expression in cultured human endothelial cells. Blood. 2000; 95: 3232-3241. PMid:10807794
40. Dinarello CA. Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. Innate Immun. 2004; 10: 201-222.
41. Reis RS, Horn F. Enteropathogenic Escherichia coli, Samonella, Shigellaand Yersinia: cellular aspects of host-bacteria interactions in enteric diseases. Gut Pathog. 2010; 2:8, doi:10.1186/1757-4749-2-8 PMid:20649986 PMCid:2921366
42. Sesso R, Almeida MA, Figueiredo MS, Bordin JO. Renal dysfunction in patients with sickle cell anemia or sickle cell trait. Braz J Med Biol Res.1998; 31: 1257-126. doi:10.1590/S0100-879X1998001000004 PMid:9876295
43. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990; 40: 63-279. doi:10.1016/S0065-3233(08)60287-9
44. Moffat K, Gibson QH. The rates of polymerization and depolymerization of sickle cell hemoglobin. Biochem Bioph Res Co. 1974; 61: 237-242. doi:10.1016/0006-291X(74)90558-0
45. Boggs DR, Hyde F, Srodes C. An unusual pattern of neutrophil kinetics in sickle cell anemia. Blood. 1973; 41: 59-62. PMid:4682080
46. Ahmed SG, Uraka AJ. Eosinopenia as a marker of infection in patients with sickle cell anaemia: a preliminary report. Int J Biomed Health Sci. 2010; 6: 57-61.
47. Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008; 12: R59 doi: 10.1186/cc6883. doi:10.1186/cc6883 PMid:18435836 PMCid:2447615
48. Gil H, Magy N, Mauny E, Dupond JL. Value of eosinopenia in inflammatory disorders: an old marker revisited. Rev. Med. Interne. 2003; 7: 431-431. doi:10.1016/S0248-8663(03)00138-3
49. Tanabe A, Kobayashi Y, Usui T. Enhancement of human neutrophil oxygen consumption by chemotactic factors. Cell Mol life Sci. 1983; 39: 604-606. doi:10.1007/BF01971119 PMid:6852196
50. Ho CH. White blood cell and platelet counts could affect whole blood viscosity. J Chin Med Assoc. 2004; 67: 394-397. PMid:15553798
51. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996; 87: 4440-4447. PMid:8639806
52. Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002; 99: 3047-3051. doi:10.1073/pnas.052522799 PMid:11880644 PMCid:122470
53. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia: clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75:300-326. doi:10.1097/00005792-199611000-00002 PMid:8982148
54. Anwar F, Abdelaal M, Albaiti A, Felimban S. Sickle cell disease: splenectomy and thrombocytosis. Transfusion. 2008; 48: 10-11. doi:10.1111/j.1537-2995.2007.01500.x PMid:18184234
55. Chen JL, Afsari K. Reactive thrombocytosis caused by infection. Infect Med. 2002; 19: 480-483.
56. Mehta P, Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J Pediatr. 1980; 96: 209-213. doi:10.1016/S0022-3476(80)80804-3
57. Ibanga IA. Significance of platelet activation in sickle cell anaemia. Niger J Med. 2006; 15:148-150. PMid:16805172
58. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol. 1998; 100: 741-749. doi:10.1046/j.1365-2141.1998.00627.x PMid:9531343
59. Charneski L, Congdon HB. Effects of anti-platelet and anticoagulant medications on the vaso-occlusive and thrombotic complications of sickle cell disease: A review of the literature. Am J Health-Syst Ph. 2010; 67: 895-900. doi:10.2146/ajhp090229 PMid:20484211
60. Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet. 2002; 359:1311-1312. doi:10.1016/S0140-6736(02)08273-9
61. Luzzatto L, Pinching AJ. Innate resistance to malaria: the intraerythrocytic cycle. Blood Cells. 1990; 16: 340-347.
62. Williams TN, Mwangi TW, Roberts DJ, et al. An immune basis for malaria protection by the sickle cell trait. PLos Med. 2005; 2: e128. doi:10.1371/journal.pmed.0020128 PMid:15916466 PMCid:1140945
63. Oniyangi O, Omari AAA. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database of Systematic Reviews. 2006; Issue 4. Art. No.:CD003489. doi:10.1002/14651858.CD003489.pub2 PMid:17054173
64. Orjih AU. Malaria parasite metabolism in sickle cells. Eur J Haematol. 1999; 62: 286-292. doi:10.1111/j.1600-0609.1999.tb01904.x
65. Rug M, Prescott SW, Fernandez KM, et al. The role of KAHRP domains in knob formation and cyto-adherence of P. falciparuminfected human erythrocytes. Blood. 2006; 108: 370-378. doi:10.1182/blood-2005-11-4624 PMid:16507777 PMCid:1895844
66. Mahdi NK, Ali NH. Intestinal parasites, including Cryptosporidium species, in Iraqi patients with sickle-cell anaemia. Eastern Medit Health J. 2002; 8.
67. Sodipo JO, Padgett D, Warrie E, Olopoenia L. Parasitic infections in sickle cell crisis: Nigerian experience. J Natl Med Assoc. 1997; 89: 285-288. PMid:9145635 PMCid:2608210
68. Sarinas PS, Chitkara RK. Ascariasis and hookworm. Semin Respir Infect. 1999; 12: 130-137.
69. Acar A, Oncül O, Cavuslu S, et al. Löffler's syndrome due to Ascaris lumbricoides mimicking acute bacterial communityacquired pneumonia. Turkiye Parazitol Derg. 2009; 33: 2392-41.
70. Canalli AA, Conran N, Fattori A, et al. Increased adhesive properties of eosinophils in sickle cell disease. Exp Hematol. 2004; 32: 728-34. doi:10.1016/j.exphem.2004.04.010 PMid:15308324
71. Ong R, Doyle R. Tropical pulmonary eosinophilia. Chest. 1998; 113: 1673-1679 doi:10.1378/chest.113.6.1673 PMid:9631810
72. Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics. 2003; 112: 87-95. doi:10.1542/peds.112.1.87 PMid:12837872
73. Inaba H, Geiger TL, Lasater OE, Wang WC. A Case of Hemoglobin SC Disease With Cold Agglutinin-Induced Hemolysis. Am J Hematol. 2005; 78: 37-40. doi:10.1002/ajh.20244 PMid:15609286
74. Cassimos D, Bezirgiannidou Z, Pantelidou D, et al. Warm autoimmune hemolytic anemia following recurrent mycoplasma pneumonia infections in a child with Down syndrome. Pediatr Hematol Oncol. 2008; 25: 693-698. doi:10.1080/08880010802237492 PMid:18850483
75. Chebotar IV, Zaslavskaia MI, Konyshkina TM, Maianskii AN. IgG- and C3-dependent adhesion of neutrophils in systems with allogeneic and xenogeneic ligands. Biull Eksp Biol Med. 1991; 112: 403-4. doi:10.1007/BF00841373